Manufacturer

Leadiant Biosciences, Inc.

Country

USA

Certificates

FDA

Document

0.39 MB

Registration Date	28 Jan 2015
Share

Oncaspar®

(0)

Medicine Pharmaceuticals Product Number : 54482-301-01

Antineoplastic Agent

Drug Information

Generic

Asparginase

NDC Code

54482-301-01

Drug Class

Asparaginase

Therapeutic Class

Antineoplastic

Dosage form

Solution

Route of Administration

SUBCUTANEOUS

Therapeutic Area

1.leukemia

Nanomaterials

Manufacturer Asserted

Polymeric Nanoparticle

Nanoparticle /Nanopowder

Indication

First Line Acute Lymphoblastic Leukemia (ALL) Acute Lymphoblastic Leukemia and Hypersensitivity to Asparaginase

Benefit

Oncaspar, with the generic name pegaspargase, is a PEGylated-l-asparaginase approved by the FDA in 1994. Acute lymphoblastic leukemia and chronic myelogenous leukemia are treated with this agent. It can also be used as a replacement in patients with leukemia who display hypersensitivity to E. coli-derived l-asparaginase. Oncaspar is beneficial as it is only administered every 2 weeks, while the native compound, l-asparaginase, must be administered three times per week. The less frequent administration of Oncaspar is simply the result of a longer half-life due to PEGylation. Furthermore, Oncaspar demonstrates decreased hypersensitivity and considerable total cost savings for patients.